文献速递淋巴瘤

复发难治原发纵隔B细胞淋巴瘤免疫检查点抑制剂真实世界多中心研究

A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma.
PubMed 文献 · Am J Hematol · 2026-04-10

中位随访34个月,最佳总缓解率64%、完全缓解率50%,4年无病生存率100%,5年无进展生存率60.4%、总生存率77.5%。

要点

  • 帕博利珠单抗或纳武利尤单抗-维布妥昔单抗在复发难治PMBCL中安全有效
  • 完全缓解后4年无病生存率100%,与是否接受巩固治疗无关
  • 纳武利尤单抗-维布妥昔单抗较帕博利珠单抗缓解更快更高且总生存更优

核心结论

  • 帕博利珠单抗或纳武利尤单抗-维布妥昔单抗作为复发难治PMBCL的挽救治疗安全有效。
  • 完全缓解后可获得持久缓解,且不依赖巩固治疗,提示免疫检查点抑制剂可能具有治愈意图。

研究设计与样本

  • 意大利多中心回顾性观察性PRIMICI研究,真实世界超说明书用药场景。
  • 中位随访34个月。

主要发现

  • 最佳总缓解率为64%(n=50),完全缓解率为50%(n=37)。
  • 37例完全缓解患者中,11例接受巩固治疗、26例继续免疫检查点抑制剂治疗,完全缓解稳定且与巩固治疗无关,4年无病生存率100%。
  • 估计5年无进展生存率为60.4%(95%CI 48.3%-70.6%),5年总生存率为77.5%(95%CI 65.8%-85.6%)。
  • 纳武利尤单抗-维布妥昔单抗较帕博利珠单抗缓解更快、缓解率更高且总生存更优。
  • 2020年后因CAR-T挽救治疗的使用,总生存显著改善。

临床怎么用

  • 复发难治PMBCL患者可考虑帕博利珠单抗或纳武利尤单抗-维布妥昔单抗作为挽救治疗。
  • 达到完全缓解后,是否需巩固治疗应个体化评估,部分患者可继续免疫检查点抑制剂治疗。
  • 纳武利尤单抗-维布妥昔单抗可能优先用于需快速起效或追求更高缓解率的患者。

局限性

  • 回顾性观察性研究,真实世界超说明书用药场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of immune checkpoint inhibitors (ICIs) has deeply improved the outcome of relapsed or refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) patients. However, real-world data are still limited, and several aspects, including the need for consolidation strategies, remain to be fully elucidated. We report the results of the multicenter Italian retrospective observational PRIMICI study on R/R PMBCL patients treated with ICIs in a real-life (off-label) setting. Seventy-four patients, 42 treated with pembrolizumab and 32 with nivolumab-brentuximab vedotin (nivo-BV), were enrolled. The median follow-up was 34 months. The best overall response and complete response (CR) rates were 64% (n = 50) and 50% (n = 37), respectively. Of the 37 patients in CR, 11 received a consolidation treatment and 26 patients continued ICIs; CR were stable, independently from the use of consolidation, with a 4-year disease-free survival of 100%. The estimated 5-year progression-free survival (PFS) and overall survival (OS) were 60.4% (95% confidence interval [C.I.] 48.3%-70.6%) and 77.5% (95% C.I. 65.8%-85.6%), respectively. Nivo-BV was associated with faster and higher response rates and better OS compared to pembrolizumab. OS significantly improved after 2020 due to the use of salvage treatment with CAR T-cells. In conclusion, this study supported the safety and effectiveness of pembrolizumab or nivo-BV as a salvage therapy in R/R PMBCL patients. Importantly, the chance to obtain long-lasting responses, regardless of the use of a consolidation treatment, indicates that ICIs may be used with a curative intent in a significant subset of patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Gugliotta G, Argnani L, Cantelli M, et al. A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma. Am J Hematol. 2026. PMID: 41960655. doi:10.1002/ajh.70317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。